Phase 2 Study with Baker's Antifol in Solid Tumors

Victorio Rodriguez, Stephen P. Richman, Robert S. Beniamin, Michael A. Burgess, William K. Murphy, Manuel Valdivieso, Robert L. Banner, Jordan U. Gutterman, Gerald P. Bodey, Emil J. Freireich

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.

Original languageEnglish (US)
Pages (from-to)980-983
Number of pages4
JournalCancer Research
Issue number4
StatePublished - Apr 1976
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase 2 Study with Baker's Antifol in Solid Tumors'. Together they form a unique fingerprint.

Cite this